adalimumab
adalimumab: sourced relationships with 1 company · 15 clinical trials tracked · 1 FDA decision.
adalimumab evidence translation
What we can confirm
1 FDA record · 15 tracked trials
What it means
What to watch
Prepared research question
How could adalimumab → PFE affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 2 study sponsors
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| PFIZER INC (PFE) Reported 2019-11-15 · Current development: unknownSource | Approved |
| PFIZER INC (PFE) Reported 2019-11-15 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (15)showing 10 most recent
Comparative Study Between Apremilast and Adalimumab in Psoriatic Arthritis Patients
Primary endpoint: Disease Activity Index for Psoriatic Arthritis
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
Primary endpoint: Change in Disease Activity Score (DAS) 28
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Primary endpoint: Stimulated C-peptide AUC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
Primary endpoint: Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Open-label, Randomized, Assessor-blinded, Efficacy, Safety, Tolerability, and Pharmacokinetics Study of Subcutaneous Risankizumab With an Adalimumab Reference Arm in Children With Active Juvenile Psoriatic Arthritis
Primary endpoint: Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30)
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn's Disease (CD)
Primary endpoint: Part A: Percentage of Participants With an Endoscopic Response Based on the Simple Endoscopic Score for (SES-CD) at Week 26
A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and Who Had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH)
Primary endpoint: Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Psoriatic Arthritis
Primary endpoint: Percentage of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12
Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Moderate to Severe Hidradenitis Suppurativa
Primary endpoint: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Primary endpoint: Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with adalimumab?
adalimumab has dated SEC/FDA relationship records for PFIZER INC.
How many clinical trials involve adalimumab?
BioSniper tracks 15 clinical trials involving adalimumab.
What is adalimumab's latest FDA decision?
The most recent tracked FDA decision for adalimumab is Approval, dated November 15, 2019.